Peripheral Neuropathy Trial, Recruiting NCT06945380 Sponsor: Mayo Clinic Condition: Peripheral Neuropathy
Back to Peripheral Neuropathy

Peripheral Neuropathy Trial, Recruiting

NCT06945380
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For patients:

  • People aged 18 or older
  • People who speak and read English
  • People who have access to the internet
  • People who received chemotherapy (a type known to affect the nerves) as part of their cancer treatment
  • People who currently have moderate to severe numbness, tingling, or pain in their hands or feet, rating it 4 or higher on a 0–10 scale
  • People whose last chemotherapy treatment was at least 6 months ago, and who are not expected to need more chemotherapy during the study period

For caregivers:

  • A spouse, partner, family member (such as an adult child, parent, or other relative), friend, or another person chosen by the patient to support them and take part in the study activities

Who may not be able to join:

For patients:

  • People whose nerve symptoms may be caused by something other than chemotherapy, such as diabetes
  • People currently taking a medication that is known to cause nerve damage
  • People who have had oncology massage therapy specifically for nerve symptoms in the past 3 months
  • People with lymphedema (fluid build-up causing swelling) that is not considered stable — if a patient has a history of lymphedema, a certified lymphedema therapist must confirm the condition is stable before they could be considered (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Cindy Tofthagen, PhD, RN, Mayo Clinic

Phone: 904-953-3972

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
27 May 2025
Est. completion
31 May 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in chemotherapy-induced peripheral neuropathy (CIPN) (Patient); Change in caregiver esteem (Caregiver); Change in attitude toward caregiving with CIPN (Caregiver)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov